• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

    2.340 -0.260 (-10.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,129,948
    Open 2.570
    Bid (Size) 2.330 (1,900)
    Ask (Size) 2.340 (3,900)
    Prev. Close 2.600
    Today's Range 2.330 - 2.590
    52wk Range 0.4350 - 3.040
    Shares Outstanding 85,029,042
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Century Therapeutics (NASDAQ:IPSC) Reports Narrower Loss, Extended Cash Runway to 2029 ↗
    Via Chartmill
    News headline image
    Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +135.2%
    +135.2%
    1 Month
    -3.3%
    -3.3%
    3 Month
    +21.9%
    +21.9%
    6 Month
    +310.2%
    +310.2%
    1 Year
    +333.3%
    +333.3%

    More News

    Read More
    News headline image
    Century Therapeutics to Participate in Upcoming Investor Conferences in March
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Reports Flat Loss in Fiscal Q2 ↗
    Via The Motley Fool
    News headline image
    Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday ↗
    Via Benzinga
    News headline image
    Demystifying Century Therapeutics: Insights From 4 Analyst Reviews ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Century Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Century Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Century Therapeutics, Inc. - Common Stock trade on?
    Century Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Century Therapeutics, Inc. - Common Stock?
    The ticker symbol for Century Therapeutics, Inc. - Common Stock is IPSC on the Nasdaq Stock Market
    What is the current price of Century Therapeutics, Inc. - Common Stock?
    The current price of Century Therapeutics, Inc. - Common Stock is 2.340
    When was Century Therapeutics, Inc. - Common Stock last traded?
    The last trade of Century Therapeutics, Inc. - Common Stock was at 04/20/26 04:00 PM ET
    What is the market capitalization of Century Therapeutics, Inc. - Common Stock?
    The market capitalization of Century Therapeutics, Inc. - Common Stock is 198.97M
    How many shares of Century Therapeutics, Inc. - Common Stock are outstanding?
    Century Therapeutics, Inc. - Common Stock has 199M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.